Nijmegen Institute for Scientist-Practitioners in Addiction

Does naltrexone affect craving in abstinent opioid-dependent patients?

TitelDoes naltrexone affect craving in abstinent opioid-dependent patients?
PublicatietypeJournal Article
Jaar van publicatie2007
AuteursDijkstra BAG, DeJong CA, Bluschke SM, Krabbe PFM, van der Staak CPF
UitgaveAddict Biol
Publicatiedatum2007 Jun
TrefwoordenAdult, Female, Heroin, Heroin Dependence, Humans, Longitudinal Studies, Male, Methadone, Middle Aged, Motivation, Naltrexone, Narcotic Antagonists, Opioid-Related Disorders, Questionnaires, Recurrence, Substance Abuse Detection, Substance Withdrawal Syndrome

Naltrexone blocks the opioid receptors that modulate the release of dopamine in the brain reward system and therefore blocks the rewarding effects of heroin and alcohol. It is generally assumed that naltrexone leads to reduction of craving, but few studies have been performed to prove this. The purpose of the present study was to examine the effect of the administration of naltrexone on craving level after rapid opioid detoxification induced by naltrexone. A naturalistic study was carried out in which patients were followed during 10 months after rapid detoxification. Data about abstinence, relapse, and naltrexone use were collected by means of urine specimens. Craving was measured by the visual analogue scale craving, the Obsessive Compulsive Drug Use Scale, and the Desires for Drug Questionnaire. Results showed that patients who relapsed in opioid use experienced obviously more craving than abstinent people. Patients who took naltrexone did not experience significant less craving than those who did not. These results suggest that the use of opioids is associated with increased craving and that abstinence for opioids is associated with less craving, independent of the use of naltrexone. This is in contrast to the general opinion. Because of the naturalistic design of the study, no firm conclusions can be drawn, but the results grounded the needs of an experimental study.

Alternatieve uitgaveAddict Biol
PubMed ID17508990